Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02400346 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
NCT02400346 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 132 participants.
The verdict
NCT02400346, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment
Interventions
- DRUG ADT
- DRUG Adjunct brexpiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02400346
The ClinicalTrials.gov registry entry for NCT02400346 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ADT is the first listed.
NCT02400346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02400346 about?
NCT02400346 is a clinical study titled "Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment". The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment
What is the current status of trial NCT02400346?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2015-03. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02400346?
The interventions under investigation include: ADT (DRUG), Adjunct brexpiprazole (DRUG).
Who is sponsoring clinical trial NCT02400346?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.